Portal de Periódicos da CAPES

Gynaecological aspects of the levonorgestrel‐releasing intrauterine system

1997; Wiley; Volume: 104; Issue: 3 Linguagem: Inglês

10.1111/j.1471-0528.1997.tb11455.x

1471-0528

Frances Sturridge, John Guillebaud,

Assisted Reproductive Technology and Twin Pregnancy

BJOG: An International Journal of Obstetrics & GynaecologyVolume 104, Issue 3 p. 285-289 Gynaecological aspects of the levonorgestrel-releasing intrauterine system Frances Sturridge, Frances Sturridge Research Registrar Margaret Pyke Family Planning Centre, 73 Charlotte Street, LondonSearch for more papers by this authorJohn Guillebaud, John Guillebaud Professor (Family Planning and Reproductive Health) and Medical Director Margaret Pyke Family Planning Centre, 73 Charlotte Street, LondonSearch for more papers by this author Frances Sturridge, Frances Sturridge Research Registrar Margaret Pyke Family Planning Centre, 73 Charlotte Street, LondonSearch for more papers by this authorJohn Guillebaud, John Guillebaud Professor (Family Planning and Reproductive Health) and Medical Director Margaret Pyke Family Planning Centre, 73 Charlotte Street, LondonSearch for more papers by this author First published: 19 August 2005 https://doi.org/10.1111/j.1471-0528.1997.tb11455.xCitations: 24Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Mirena Product Monograph, 1995 and Data Sheet for Mirena. Turku , Finland : Leiras Oy, 1995. 2 Sivin I, Stern J, Diaz J. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel releasing or copper TCu 380 Ag intrauterine contraceptive devices. Am J ObstetGynecol 1992; 166: 1208–1213. 3 Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992; 46: 575–584. 4 Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel-and copper-releasing devices. Obstet Gynecol 1990; 77: 261–264. 5 Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) lUCDs during five years of use: a randomised comparative trial. Contraception 1994; 49: 56–72. 6 Andeisson K, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 690–694. 7 Hallberg L, Hogdahl A-M, Nilsson L, Rybo G. Menstrual blood loss–a population study. Acta Obstet Gynecol Scand 1996; 45: 320–351. 8 Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990; 22: 85–90. 9 Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 meg/day and the copper TCu 380 Ag intrauterine contraceptive devices: amulticenter study. FertilSteril 1994; 61: 70–77. 10 Bounds W, Robinson G, Kubba A, Guillebaud J. Clinical experience with a levonorgestrel-releasing intrauterine contraceptive device (LNG-IUCD) as a contraceptive and in the treatment of menorrhagia. Br J Fam Plann 1993; 19: 193–194. 11 Nilsson CG, Lahteenmaki P, Luukainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUCD. Contraception 1980; 21: 225–233. 12 Sivin I, Stern J, Coutinho E et al. Prolonged intrauterine contraception: a seven year randomized study of the levonorgestrel 20 meg/day (LNg 20) and the copper T 380 Ag lUCDs. Contraception 1991; 44: 473–80. 13 Singer A, Ilomi A. Successful treatment of fibroids using an intrauterine progesterone device [abstract]. 14th World Congress of Gynaecology and Obstetrics (FIGO); Montreal , Canada ; 2430 September 1994. 14 Pekonen F, Nyman T, Lahteenmaki P et al. Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. J din Endo Metab 1992; 75: 660–664. 15 Franks A, Beral V, Cates W, Hogue C. Contraception and ectopic pregnancy risk. Am J Obstet Gynecol 1990; 163: 1120–1123. 16 Luukkainen T, Allonen H, Haukkamaa M et al. Five years experience with levonorgestrel lUCDs. Contraception 1986; 33: 139–148. 17 Luukainen T. The levonorgestrel-releasing IUCD. Br J Fam Plann 1993; 19: 221–224. 18 Tayob Y, Adams J, Jacobs H, Guillebaud J. Ultrasound demonstration of increased frequency of fumctional ovarian cysts in women using progestogen-only oral contraception Br J Obstet Gynaecol 1985; 92: 1003–1009. 19 Robinson G, Bounds W, Kubba A, Adams J, Guillebaud J. Functional ovarian cysts associated with the levonorgestrel releasing intrauterine device. Br J Fam Plann 1989; 14: 131–132. 20 Xiao B, Zeng T, Shangchun W, Sun H, Xaio N. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use Contraception 1995; 51: 359–365. 21 Nilsson C, Pertti L, Lahteenmaki A, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing device FertilSteril 1984; 41: 52–55. 22 Barbosa I, Bakos O, Olsson S, Odlind V, Johansson E. Ovarian function during use of a levonorgestrel-releasing IUCD. Contraception 1990; 42: 51–66. 23 Guillebaud J, Bounds W. Control of pain associated with intrauterine device insertion using mefenamic acid. Research and Clinical Forums 1983; 5: 69–74. 24 Heikkila M, Luukkainen T. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device. Contraception 1982; 25: 279–292. 25 Chi L, Farr G. The non-contraceptive effects of the levonorgestrel-releasing intrauterine device. Adv Contracep 1994; 10: 271–285. 26 The management of menorrhagia. Effective Health Care 1995; Bulletin No. 9. Leeds : University of Leeds, 1995. 27 Puolakka J, Nilsson C, Haukkamaa M et al. Conservative treatment of excessive uterine bleeding and dysmenorrhoea with levonergestrel intrauterine system as an alternative to hysterectomy. Acta Obstet Gynecol Scand 1996; 75 (Suppl): 82. 28 Sculpher MJ, Dwyer N, Byford S, Stirrat GM. Randomised trial comparing hysterectomy and transcervical endometrial resection: effect on health related quality of life and costs two years after surgery. Br J Obstet Gynaecol 1996; 103: 142–149. 29 Gasparri F, Scarselli G, Colafranceschi M, Taddei G, Tantini C, Savino L. Management of precancerous lesions of the endometrium. In: H Ludwig, K Thomsen, editors. Gynaecology and Obstetrics. Berlin : Springer-Verlag, 1986. 30 Scarselli G, Tantini C, Colafranceschi M. Levonorgestrel-Nova-T and precancerous lesions of the endometrium. Ear J Gynecol Oncol 1988; 9: 284–286. 31 Perino A, Quartararo P, Catinella E, Geneva G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel-releasing intrauterine devices. Acta Europaea Fertilitatis 1987; 18: 137–140. 32 Andersson K, Mattsson L, Rybo G, Stadberg E. Intrauterine release of levonorgestrel—a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 79: 963–967. 33 Raudaskoski T, Lahti E, Kauppila A, Apaja-Sarkkinen M, Laatikainen T. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. Am J Obstet Gynecol 1994; 179: 114–119. 34 Neven P, De Muylder X, Van Belle Y, Campo R, Vanderick G. Tamoxifen and the uterus. BMJ 1994; 309: 1313–1314. 35 Smith RN, Studd JW, Zamblera D, Holland EFN. A randomised comparison over 8 months of 100 meg and 200 meg twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475–484. 36 Mann R. Unlicensed medicines and the use of drugs in unlicensed indications. In: A Goldberg, I Dodd-Smith, editors. Pharmaceutical Medicine and the Law, Vol 8. London : Royal College of Physicians, 1991: 103–110. Citing Literature Volume104, Issue3March 1997Pages 285-289 ReferencesRelatedInformation